Logo image of 9VC.DE

ATAI BECKLEY NV (9VC.DE) Stock Fundamental Analysis

Europe - Frankfurt Stock Exchange - FRA:9VC - NL0015000DX5 - Common Stock

3.735 EUR
+0.14 (+3.98%)
Last: 12/23/2025, 7:00:00 PM
Fundamental Rating

3

Taking everything into account, 9VC scores 3 out of 10 in our fundamental rating. 9VC was compared to 54 industry peers in the Pharmaceuticals industry. While 9VC has a great health rating, there are worries on its profitability. 9VC is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year 9VC has reported negative net income.
In the past year 9VC has reported a negative cash flow from operations.
In the past 5 years 9VC always reported negative net income.
In the past 5 years 9VC always reported negative operating cash flow.
9VC.DE Yearly Net Income VS EBIT VS OCF VS FCF9VC.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

9VC's Return On Assets of -62.24% is on the low side compared to the rest of the industry. 9VC is outperformed by 83.33% of its industry peers.
The Return On Equity of 9VC (-93.44%) is worse than 79.63% of its industry peers.
Industry RankSector Rank
ROA -62.24%
ROE -93.44%
ROIC N/A
ROA(3y)-52.42%
ROA(5y)-70.02%
ROE(3y)-67.79%
ROE(5y)-86.99%
ROIC(3y)N/A
ROIC(5y)N/A
9VC.DE Yearly ROA, ROE, ROIC9VC.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

9VC does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
9VC.DE Yearly Profit, Operating, Gross Margins9VC.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -20K -40K -60K

More info and screens

8

2. Health

2.1 Basic Checks

9VC does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for 9VC has been increased compared to 1 year ago.
The number of shares outstanding for 9VC has been increased compared to 5 years ago.
The debt/assets ratio for 9VC is higher compared to a year ago.
9VC.DE Yearly Shares Outstanding9VC.DE Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 50M 100M 150M
9VC.DE Yearly Total Debt VS Total Assets9VC.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

An Altman-Z score of 6.42 indicates that 9VC is not in any danger for bankruptcy at the moment.
9VC's Altman-Z score of 6.42 is amongst the best of the industry. 9VC outperforms 87.04% of its industry peers.
9VC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 6.42
ROIC/WACCN/A
WACC7.43%
9VC.DE Yearly LT Debt VS Equity VS FCF9VC.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

A Current Ratio of 7.90 indicates that 9VC has no problem at all paying its short term obligations.
The Current ratio of 9VC (7.90) is better than 98.15% of its industry peers.
A Quick Ratio of 7.90 indicates that 9VC has no problem at all paying its short term obligations.
The Quick ratio of 9VC (7.90) is better than 98.15% of its industry peers.
Industry RankSector Rank
Current Ratio 7.9
Quick Ratio 7.9
9VC.DE Yearly Current Assets VS Current Liabilites9VC.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

4

3. Growth

3.1 Past

9VC shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by 0.00%.
Looking at the last year, 9VC shows a decrease in Revenue. The Revenue has decreased by -1.91% in the last year.
Measured over the past years, 9VC shows a very negative growth in Revenue. The Revenue has been decreasing by -75.28% on average per year.
EPS 1Y (TTM)0%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-75%
Revenue 1Y (TTM)-1.91%
Revenue growth 3Y-75.28%
Revenue growth 5YN/A
Sales Q2Q%1772.5%

3.2 Future

Based on estimates for the next years, 9VC will show a quite strong growth in Earnings Per Share. The EPS will grow by 12.71% on average per year.
9VC is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 226.91% yearly.
EPS Next Y30.67%
EPS Next 2Y22.22%
EPS Next 3Y14.8%
EPS Next 5Y12.71%
Revenue Next Year468.61%
Revenue Next 2Y-38.09%
Revenue Next 3Y24.11%
Revenue Next 5Y226.91%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
9VC.DE Yearly Revenue VS Estimates9VC.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
9VC.DE Yearly EPS VS Estimates9VC.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 2 3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for 9VC. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for 9VC. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
9VC.DE Price Earnings VS Forward Price Earnings9VC.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
9VC.DE Per share data9VC.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 -0.4 -0.6

4.3 Compensation for Growth

9VC's earnings are expected to grow with 14.80% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y22.22%
EPS Next 3Y14.8%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for 9VC!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

ATAI BECKLEY NV

FRA:9VC (12/23/2025, 7:00:00 PM)

3.735

+0.14 (+3.98%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-12 2025-11-12/bmo
Earnings (Next)03-16 2026-03-16/amc
Inst Owners12.05%
Inst Owner ChangeN/A
Ins Owners3.7%
Ins Owner ChangeN/A
Market Cap1.36B
Revenue(TTM)308.00K
Net Income(TTM)-149.27M
Analysts83.53
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-74.59%
Min EPS beat(2)-131.54%
Max EPS beat(2)-17.64%
EPS beat(4)1
Avg EPS beat(4)-48.58%
Min EPS beat(4)-131.54%
Max EPS beat(4)17.15%
EPS beat(8)3
Avg EPS beat(8)-34.15%
EPS beat(12)6
Avg EPS beat(12)-5.69%
EPS beat(16)8
Avg EPS beat(16)-13.8%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)2.16%
PT rev (3m)6.37%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-0.52%
EPS NY rev (1m)-26.55%
EPS NY rev (3m)-34.65%
Revenue NQ rev (1m)12.5%
Revenue NQ rev (3m)33.33%
Revenue NY rev (1m)24.85%
Revenue NY rev (3m)28.39%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 5191.31
P/FCF N/A
P/OCF N/A
P/B 10.01
P/tB 10.22
EV/EBITDA N/A
EPS(TTM)-0.69
EYN/A
EPS(NY)-0.4
Fwd EYN/A
FCF(TTM)-0.21
FCFYN/A
OCF(TTM)-0.19
OCFYN/A
SpS0
BVpS0.37
TBVpS0.37
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -62.24%
ROE -93.44%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-52.42%
ROA(5y)-70.02%
ROE(3y)-67.79%
ROE(5y)-86.99%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1203.88%
Cap/Sales 3521.75%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.9
Quick Ratio 7.9
Altman-Z 6.42
F-Score4
WACC7.43%
ROIC/WACCN/A
Cap/Depr(3y)268.35%
Cap/Depr(5y)673.01%
Cap/Sales(3y)220.74%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)0%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-75%
EPS Next Y30.67%
EPS Next 2Y22.22%
EPS Next 3Y14.8%
EPS Next 5Y12.71%
Revenue 1Y (TTM)-1.91%
Revenue growth 3Y-75.28%
Revenue growth 5YN/A
Sales Q2Q%1772.5%
Revenue Next Year468.61%
Revenue Next 2Y-38.09%
Revenue Next 3Y24.11%
Revenue Next 5Y226.91%
EBIT growth 1Y18.39%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-5.8%
EBIT Next 3Y-18.5%
EBIT Next 5Y-6.5%
FCF growth 1Y3.34%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y14.22%
OCF growth 3YN/A
OCF growth 5YN/A

ATAI BECKLEY NV / 9VC.DE FAQ

What is the ChartMill fundamental rating of ATAI BECKLEY NV (9VC.DE) stock?

ChartMill assigns a fundamental rating of 3 / 10 to 9VC.DE.


What is the valuation status of ATAI BECKLEY NV (9VC.DE) stock?

ChartMill assigns a valuation rating of 0 / 10 to ATAI BECKLEY NV (9VC.DE). This can be considered as Overvalued.


What is the profitability of 9VC stock?

ATAI BECKLEY NV (9VC.DE) has a profitability rating of 0 / 10.


Can you provide the expected EPS growth for 9VC stock?

The Earnings per Share (EPS) of ATAI BECKLEY NV (9VC.DE) is expected to grow by 30.67% in the next year.